280 related articles for article (PubMed ID: 30231344)
1. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Raj N; Fazio N; Strosberg J
Am Soc Clin Oncol Educ Book; 2018 May; 38():292-299. PubMed ID: 30231344
[TBL] [Abstract][Full Text] [Related]
2. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
6. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
8. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Öberg K; Knigge U; Kwekkeboom D; Perren A;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii124-30. PubMed ID: 22997445
[No Abstract] [Full Text] [Related]
9. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion.
Iyer R; Phan AT; Boudreaux JP
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):18-19. PubMed ID: 28654026
[No Abstract] [Full Text] [Related]
11. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
Neychev V; Kebebew E
Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
[TBL] [Abstract][Full Text] [Related]
12. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
Ye C; Yuan CH; Li G; Zheng L; Xiu DR
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
[TBL] [Abstract][Full Text] [Related]
13. Intervention in gastro-enteropancreatic neuroendocrine tumours.
Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
[TBL] [Abstract][Full Text] [Related]
14. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
16. Aggressive gastro-entero-pancreatic neoplasms.
Coriat R
Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
[No Abstract] [Full Text] [Related]
17. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
Bellizzi AM
Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
[TBL] [Abstract][Full Text] [Related]
19. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
Karakuş E; Helvacı A; Ekinci O; Dursun A
Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
[TBL] [Abstract][Full Text] [Related]
20. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
